<DOC>
	<DOCNO>NCT02071355</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics ( body medication ) TMC435 multiple oral dos 100 150 mg TMC435 daily 7 day healthy Chinese participant .</brief_summary>
	<brief_title>A Study Examine Pharmacokinetics , Safety Tolerability Multiple Oral Doses TMC435 Healthy Chinese Participants</brief_title>
	<detailed_description>This open-label ( [ participant investigator ] know treatment participant receive ) randomize ( study medication assign chance ) study . The study consist 3 phase : screening phase ( within 21 day prior administration study medication ) , treatment phase ( day -1 [ 1 day administration study medication ] Day 10 include pharmacokinetics sample collection ) , follow-up phase ( 16 day last dose study medication dropout [ withdrawal consent ] ) . Approximately 32 healthy participant equally divide 2 group ( Group 1 Group 2 ) receive TMC435 7 day . Safety evaluate assessment adverse event , clinical laboratory test , vital sign , physical examination monitor various timepoints throughout study . The total duration study participation participant approximately 47 day .</detailed_description>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Healthy Chinese participant basis physical examination , medical history , vital sign , 12lead electrocardiogram , clinical laboratory test perform screen Must nonsmoking least 3 month prior screen confirm urine cotinine test A Body Mass Index ( BMI ) 18.0 30.0 kg/square meter , extremes include ( BMI calculate BMI = body weight kg divide square height meter ) Participants must agree use one contraception method define protocol Positive human immunodeficiency virus type 1 2 ; syphilis ; hepatitis A , B C infection screen History presence liver renal clearance insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , neoplastic , metabolic disturbance History evidence current use alcohol , barbiturate , amphetamine , recreational narcotic medicine use Any history significant skin disease limit , rash eruption , allergy , dermatitis , eczema ( inflammation skin ) , psoriasis ( inflammatory skin disease ) , urticarial ( raise itchy rash appear skin ) Female participant breastfeed screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Chinese participant</keyword>
	<keyword>TMC435</keyword>
	<keyword>Multiple oral dos</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
</DOC>